Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 1 of 1 for:    Phase 2 Study of Zevalin (ibritumomab tiuxetan) versus Zevalin and motexafin gadolinium
Previous Study | Return to List | Next Study

Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma

This study has been terminated.
(Due to business reasons.)
Information provided by (Responsible Party):
Spectrum Pharmaceuticals, Inc Identifier:
First received: March 6, 2012
Last updated: March 25, 2013
Last verified: March 2013
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: July 2016
  Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)